公开(公告)号：US20130095067A1

公开(公告)日：2013-04-18

申请号：US13580710

申请日：2011-02-24

Applicant: Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

Inventor： Jonathan Alleman Baker ,  Matthew Colin Thor Fyfe

IPC: A61K31/135 ,  A61K38/21 ,  A61K31/137 ,  A61K31/131 ,  A61K31/165 ,  A61K45/06

CPC classification number: A61K31/135 ,  A61K31/131 ,  A61K31/137 ,  A61K31/15 ,  A61K31/165 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

Abstract translation: 本发明提供治疗或预防肝炎病毒科感染和由肝炎病毒科感染引起的疾病。 特别地，本发明提供影响Hepadnaviridae利用宿主细胞机制作为病毒生命周期的一部分的能力的组合物和方法。 本发明涉及干扰病毒利用宿主细胞机制与LSD1抑制剂的正常能力的发现降低HBV复制。 因此，根据本发明的肝炎病毒科感染和肝炎病毒科引起的疾病的治疗和预防包括向需要治疗的个体施用治疗有效量的LSD1抑制剂。 需要治疗的个体可以是人或例如另一种哺乳动物。

公开(公告)号：US20120059014A1

公开(公告)日：2012-03-08

申请号：US13255531

申请日：2010-03-12

Applicant: Oscar Barba ,  Tom Banksia Dupree ,  Peter Timothy Fry ,  Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  Thomas Martin Krulle ,  Karen Lesley Schofield ,  Donald Smyth ,  Thomas Staroske ,  Alan John William Stewart ,  David French Stonehouse ,  Simon Andrew Swain ,  David Matthew Withall

Inventor： Oscar Barba ,  Tom Banksia Dupree ,  Peter Timothy Fry ,  Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  Thomas Martin Krulle ,  Karen Lesley Schofield ,  Donald Smyth ,  Thomas Staroske ,  Alan John William Stewart ,  David French Stonehouse ,  Simon Andrew Swain ,  David Matthew Withall

IPC: A61K31/506 ,  C07D413/14 ,  A61K31/4545 ,  A61K31/501 ,  A61P9/12 ,  A61P3/04 ,  A61P3/00 ,  A61P3/08 ,  A61P3/06 ,  A61P7/00 ,  C07D401/14 ,  A61P3/10

CPC classification number: C07D403/12

Abstract: The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

Abstract translation: 本发明涉及具有作为GPR119激动剂的活性的下式（I）的治疗性化合物，并且可用于治疗包括II型糖尿病的代谢紊乱。

公开(公告)号：US20100105732A1

公开(公告)日：2010-04-29

申请号：US12522023

申请日：2008-01-04

Applicant: Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Simon Andrew Swain ,  Lisa Sarah Bertram

Inventor： Matthew Colin Thor Fyfe ,  Revathy Perpetua Jeevaratnam ,  John Keily ,  Simon Andrew Swain ,  Lisa Sarah Bertram

IPC: A61K31/4545 ,  C07D213/71 ,  C07D213/82 ,  A61P3/04 ,  A61P3/10 ,  A61P3/00 ,  A61P9/12 ,  A61P9/10 ,  A61P9/00

CPC classification number: C07D413/14

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

公开(公告)号：US20100048631A1

公开(公告)日：2010-02-25

申请号：US12522010

申请日：2008-01-04

Applicant: Matthew Colin Thor Fyfe ,  John Keily ,  Martin Procter ,  David French Stonehouse ,  Simon Andrew Swain

Inventor： Matthew Colin Thor Fyfe ,  John Keily ,  Martin Procter ,  David French Stonehouse ,  Simon Andrew Swain

IPC: A61K31/454 ,  C07D413/04 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/12

CPC classification number: C07D413/04

Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

公开(公告)号：US20100035897A1

公开(公告)日：2010-02-11

申请号：US11794641

申请日：2005-12-30

Applicant: Stuart Edward Bradley ,  Matthew Colin Thor Fyfe ,  Gerard Hugh Thomas

Inventor： Stuart Edward Bradley ,  Matthew Colin Thor Fyfe ,  Gerard Hugh Thomas

IPC: A61K31/506 ,  C07D401/14 ,  A61K31/4545 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07D401/14

Abstract: Compounds of formula (I): R1-A-V—B—R2, wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Abstract translation: 式（I）化合物：其中V为苯基或含有至多3个N原子的6元杂芳基的R1-AVB-R2或其药学上可接受的盐为GPR116的激动剂，可用于治疗肥胖症 ，并用于治疗糖尿病。

公开(公告)号：US20090054444A1

公开(公告)日：2009-02-26

申请号：US11573464

申请日：2005-08-09

Applicant: Matthew Colin Thor Fyfe ,  Vilasben Kanji Shah

Inventor： Matthew Colin Thor Fyfe ,  Vilasben Kanji Shah

IPC: A61K31/495 ,  C07C321/00 ,  C07C381/00 ,  C07D241/10 ,  C07D237/24 ,  A61K31/415 ,  A61P3/10 ,  A61K31/50 ,  C07D231/10 ,  A61K31/192 ,  A61K31/165

CPC classification number: C07C317/44 ,  C07C2601/02 ,  C07C2601/08 ,  C07D231/40 ,  C07D237/20 ,  C07D241/20

Abstract: Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

Abstract translation: 其中R1是环烷基磺酰基的式（I）化合物或其药学上可接受的盐可用于预防和治疗高血糖症和糖尿病。